These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 16315644

  • 1. [Pathogenesis of portal hypertension].
    Montaño-Loza A, Meza-Junco J.
    Rev Invest Clin; 2005; 57(4):596-607. PubMed ID: 16315644
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Causes and pathomechanisms of oesophageal varices development.
    Paquet KJ.
    Med Sci Monit; 2000; 6(5):915-28. PubMed ID: 11208432
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.
    Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J.
    J Hepatol; 2005 Jul; 43(1):98-103. PubMed ID: 15893841
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Increased blood flow through the portal system in cirrhotic rats.
    Vorobioff J, Bredfeldt JE, Groszmann RJ.
    Gastroenterology; 1984 Nov; 87(5):1120-6. PubMed ID: 6479534
    [Abstract] [Full Text] [Related]

  • 8. [Physiopathologic basis of medical therapy of portal hypertension in cirrhosis].
    Gatta A, Bolognesi M, Sacerdoti D, Merkel C.
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():39S-47S. PubMed ID: 9004819
    [Abstract] [Full Text] [Related]

  • 9. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
    Gatta A, Bolognesi M, Merkel C.
    Mol Aspects Med; 2008 Oct; 29(1-2):119-29. PubMed ID: 18036654
    [Abstract] [Full Text] [Related]

  • 10. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.
    Wiest R, Groszmann RJ.
    Semin Liver Dis; 1999 Oct; 19(4):411-26. PubMed ID: 10643626
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic treatment of portal hypertension.
    Rodríguez-Pérez F, Groszmann RJ.
    Gastroenterol Clin North Am; 1992 Mar; 21(1):15-40. PubMed ID: 1349005
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacological control of portal hypertension.
    Polio J, Groszmann RJ.
    Prog Liver Dis; 1993 Mar; 11():231-49. PubMed ID: 8272513
    [Abstract] [Full Text] [Related]

  • 14. Molecular and structural basis of portal hypertension.
    Moreau R, Lebrec D.
    Clin Liver Dis; 2006 Aug; 10(3):445-57, vii. PubMed ID: 17162222
    [Abstract] [Full Text] [Related]

  • 15. Portal hypertension: state of the art.
    Gatta A, Sacerdoti D, Bolognesi M, Merkel C.
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):326-45. PubMed ID: 10425579
    [Abstract] [Full Text] [Related]

  • 16. Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.
    Curvêlo LA, Brabosa W, Rhor R, Lanzoni V, Parise ER, Ferrari AP, Kondo M.
    J Gastroenterol Hepatol; 2009 Sep; 24(9):1541-6. PubMed ID: 19743998
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pathophysiology of liver circulation with an overview of medical and invasive treatments.
    Bombardieri G, Conti LR.
    Rays; 1997 Sep; 22(2):196-210. PubMed ID: 9351328
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.